Texas Clinical Research Institute
Welcome,         Profile    Billing    Logout  
 5 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Abate, Nicola
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
Al-Assi, Tarek
PL8177-205, NCT05466890: Phase 2a To Evaluate PL-8177 in Subjects With Active Ulcerative Colitis (UC)

Recruiting
2
28
US
PL8177 Placebo, Placebo, PL8177, Active study medication
Palatin Technologies, Inc
Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare
04/24
08/24
Ghalib, Reem H
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated
2b
98
Europe, Canada, US, RoW
EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo
Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.
Non-Alcoholic Steatohepatitis
10/21
11/21
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
Devlin, Deborah
NCT04982835: M6®-C Artificial Cervical Disc Two-Level IDE Pivotal Study

Recruiting
N/A
263
US
M6-C Artificial Cervical Disc, ACDF
Spinal Kinetics
Cervical Disc Degenerative Disorder
12/24
12/25
NCT04469231: The Synergy Disc To Anterior Cervical Discectomy and Fusion

Active, not recruiting
N/A
175
US
Anterior Cervical Discectomy & Fusion, ACDF
Synergy Spine Solutions, MCRA
Cervical Degenerative Disc Disease
01/25
01/26
Mumm, Ian
No trials found

Download Options